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Abstract
Epidermal growth factor receptor (EGFR) pathway activation is a frequent event in human carcinomas. Mutations
in EGFR itself are, however, rare, and the mechanisms regulating EGFR activation remain elusive. Leucine-rich
immunoglobulin repeats-1 (LRIG1), an inhibitor of EGFR activity, is one of four genes identified that predict
patient survival across solid tumour types including breast, lung, melanoma, glioma, and bladder. We show that
deletion of Lrig1 is sufficient to promote murine airway hyperplasia through loss of contact inhibition and that
re-expression of LRIG1 in human lung cancer cells inhibits tumourigenesis. LRIG1 regulation of contact inhibition
occurs via ternary complex formation with EGFR and E-cadherin with downstream modulation of EGFR activity.
We find that LRIG1 LOH is frequent across cancers and its loss is an early event in the development of human
squamous carcinomas. Our findings imply that the early stages of squamous carcinoma development are driven
by a change in amplitude of EGFR signalling governed by the loss of contact inhibition.
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Introduction
Dysregulation of EGFR signalling is a common feature
of various lung diseases such as asthma, lung fibrosis,
and lung cancer [1,2]. EGFR signalling is also crucial
for lung development as Egfr-null mice have defects in
both branching and differentiation, whilst segregation
of EGFR and its ligands regulates repair [3–5].
The EGFR family is a group of four structurally sim-
ilar tyrosine kinases (EGFR, HER2/neu, ErbB-3, and
ErbB-4) that dimerize upon ligand binding. EGFR is an
important lung oncogene and is overexpressed in virtu-
ally all squamous carcinomas. Intriguingly, overexpres-
sion of EGFR is one of the earliest abnormalities in the
bronchial epithelium of smokers and is present in all
stages of pre-invasive squamous cell carcinoma includ-
ing basal cell hyperplasia, squamous metaplasia, dys-
plasia, and carcinoma in situ [6]. We hypothesize that
tissue homeostasis is maintained via strong endoge-
nous regulation of EGFR signalling and that loss of
this regulation leads to early-stage tumourigenesis.
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Leucine-rich repeats and immunoglobulin like-
domains (LRIG1) is one such inhibitor and in the
epidermis it has been found to maintain epidermal
stem cells in a non-proliferative state via negative
regulation of EGFR signalling [7,8], with its loss
being observed in psoriatic lesions and epidermal
squamous cell carcinomas [9,10]. There is, in fact,
strong bioinformatic evidence of LRIG1’s role in
tumourigenesis, with a recent study showing that
LRIG1 was one of only four mis-expressed genes that
relate to patient survival across epithelial cancer types
[11]. The mechanism for this is unknown.
In the following experiments, we show that LRIG1
is expressed in the epithelium of the upper murine
airways. Loss of Lrig1 in murine airways leads
to epithelial hyperproliferation, which is recapitu-
lated with in vitro organotypic cultures where Lrig1 -
deficient cells fail to undergo cell–cell contact
inhibition. We demonstrate that LRIG1 forms a ternary
complex between LRIG1, E-cadherin, and EGFR,
which upon cell–cell contact negatively regulates
EGFR signalling. In human lung cancer cell lines,
we show that re-expression of LRIG1 reduces cell
growth and inhibits tumourigenesis in vivo. LRIG1
LOH occurs across many tumour types and particularly
in squamous cell carcinomas. Finally, we demonstrate
that LRIG1 may be an important trigger of carcinogen-
esis at the pre-invasive carcinoma stage by showing
that LRIG1 loss is an early and consistent event in the
pathogenesis of pre-invasive lung cancer lesions.
Materials and methods
Animal experiments
Mouse husbandry and experimentation
Adult, 2- to 4-month-old mice were used for exper-
iments, housed in individually ventilated cages on a
12 h light/dark cycle, and allowed access to food and
water ad libitum . Lrig1 -null mice were a kind gift from
Sathoshi Itami [9]. All transgenic mice were main-
tained on a mixed background of 129, C57/Bl6, and
CD1 inbred strains. Homozygote-deleted Lrig1 mice
were compared with sex-matched littermate heterozy-
gote Lrig1 mice as controls. Of note, heterozygote
littermates were compared with wild-type littermates
and found to have no difference in airway epithelial
morphology, cellularity or proliferation (Supplemen-
tary Figure 1). Hence the breeding programme con-
sisted of breeding a heterozygote with a knockout to
maximize experimental mice numbers and subsequent
experiments compared heterozygote littermates with
knockouts. For experiments involving tracheal repair,
mice were anaesthetized with isofluorane and tracheas
damaged via oropharyngeal instillation of 15 µl of
2% polidocanol (a detergent agent that removes the
airway epithelium, leaving an intact basement mem-
brane) (Sigma, Dorset, UK) [12]. BrdU was injected
intraperitoneally (Zymed 00–0103; 100 µl concen-
trated reagent per 10 g body weight, intraperitoneally,
2 h pre-sacrifice). Tracheal samples were fixed in
4% paraformaldehyde and paraffin-embedded or snap-
frozen in OCT. Mice were sacrificed by sodium pento-
barbitol overdose and sentinel screenings for common
murine pathogens were used throughout the course of
these studies. All in vivo experiments involved a min-
imum sample size of five animals per group, were
repeated at least twice, and were performed under the
terms of a UK Home Office project licence.
Tissue preparation, histology, and antibody staining
Human and murine tissue sections were fixed in
10% neutral buffered formalin or 4% paraformalde-
hyde, processed, and sectioned at 4 µm thickness.
Human biopsy samples were obtained via fibre optic
bronchoscopy, with patient consent under institutional
ethical approval. Human and murine haematoxylin and
eosin (H&E) staining was performed using an auto-
mated staining system (TissueTek). All human biopsy
specimens were subjected to routine histopathological
diagnosis by two consultant lung histopathologists (MF
and AN). Air–liquid interface (ALI) culture whole-
mounts were fixed overnight in 4% paraformaldehyde
prior to antibody immunostaining.
Immunofluorescent or immunohistochemical human
and murine tissue section and/or ALI whole-mount
antibody staining followed standard conditions [13].
Species-appropriate secondary antibodies included
streptavidin-HRP (DAKO, Cambridgeshire, UK)
(Ki67) or directly conjugated Alexafluor dyes (all
other primary antibodies). For immunofluorescence or
immunohistochemistry, we used the following anti-
bodies: LRIG1 (S Itami, University of Osaka, Japan),
LRIG1 (rabbit; Abcam, Cambridge, MA, USA), K14
(rabbit; Covance, Leeds, UK), K14 (LL002) (mouse
IgG3; F Watt, CRUK, Cambridge), CCSP (goat; gift
from B Stripp, Duke University, USA) [14], acetylated
tubulin (mouse; Sigma), Ki67 (rabbit; Sigma), BrdU
(ICR1) (mouse; AbD Serotec, Kidlington, UK),
CDH1 (rat; Sigma), CDH1 (mouse; Watt, CRUK,
UK), flag1 (mouse; Sigma), and EGFR1 (mouse;
Abcam). Secondary antibodies were conjugated to
HRP, Alexa555, Alexa633 or Alexa488 (Invitrogen,
Paisley, UK). Images were acquired using a Leica TCS
Tandem or SPE confocal or an Olympus bright-field
microscope. Confocal images were imported into
Volocity software (Perkin Elmer, Bucks, UK) for
accurate measurement of intensity. Four representative
z -stack images acquired with a 40× objective were
analysed for each of three animals in Lrig-null and Het
groups. All images were post-processed using Adobe
Photoshop (Photomerge, rotate, crop, brightness, and
contrast adjustments).
Morphometry and statistical analysis
Epithelial height and cell density were determined
using Volocity image analysis software. We quanti-
fied the abundance of specific tracheal cell phenotypes
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Figure 1. Deletion of Lrig1 causes hyperproliferation of the upper airways. (a, b) Immunofluorescence with a histogram of the signal
intensity for LRIG1 in normal murine tracheal epithelium before polidocanol-generated tracheal injury (day 0), and days 2 and 7 after injury
(one-way ANOVA and Tukey’s multiple comparison test; *day 0 versus day 2, p= 0.004). (c–g) Comparison of Lrig1−/− mice with littermate
controls. (c–f) H&E staining with quantification of tracheal epithelial thickness and number of cells per 200 µm of basement membrane
(unpaired t-test, mean± SEM, 24.9± 1.2 µm versus 19.1± 1.7 µm; p= 0.03 and 118.3± 8.9 versus 81.3± 3.0; *p= 0.001). (g) Ki67
immunostaining and corresponding quantification (Mann–Whitney test, 8.6%± 1.1% versus 3.4%± 0.3%, p= 0.03). (h) Immunostaining
of phospho-EGFR in Lrig1−/− mice (KO) and littermate tracheal epithelium before polidocanol-generated tracheal injury with fluorescence
intensity histograms at (i) day 0 (*unpaired t-test p= 0.04), and (j) day 2 (p= 0.85) and (k) day 7 (*p= 0.04) after injury. (l) Proliferation
index of Ki67 immunoreactivity in Lrig1−/− and littermate control tracheal epithelium day 7 post-injury. (All statistical values, mean± SEM;
**Mann–Whitney test, p= 0.03.) Scale bars= 20 µm.
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as a function of epithelial basement membrane length
[15]. Two-tailed unpaired t-tests were performed to
assess the significance of differences between epithelial
heights and signal intensity between two groups and
the Mann–Whitney U -test was used for cell pheno-
type and proliferation. One-way ANOVA and Tukey’s
multiple comparison test were performed to assess
the signal intensity from fluorescent images between
three groups. Statistical significance was accepted at
p < 0.05 for all analyses, and error bars represent the
standard error of the mean. All statistical analyses were
performed using GraphPad Prism and Microsoft Excel.
Human cell culture and retroviral infection
A549 and H357 cells were transduced with pBabePuro-
Lrig1Flag and pBabe Puro [8]. A549 cells were
grown in DMEM + 10% FBS + L-glutamine. Trans-
duction of cancer cells was carried out as previously
described [16]. Briefly, ecotropic Phoenix packaging
cells were transiently transfected with retroviral vec-
tors, and virus-containing supernatants were used to
infect AM12 packaging cells, as described previously
[17]. Stably transduced AM12 cells were cultured with
2.5 µg/ml puromycin. Cancer cells were transduced
with retroviral vectors either by co-culture with AM12
cells [18] or by incubation with AM12 supernatant
[17]. All cells were obtained from Cancer Research
UK, London Research Institute (CRUK, London, UK)
and were authenticated by the integrin expression pro-
file (H357) and SpC expression (A549) [19].
Murine in vitro culture
Mouse tracheal epithelial cells (MTECs) were har-
vested using aseptic techniques, pooled, cleaned, and
digested in pronase as previously described [20].
Enzyme isolated cells were counted and seeded in
12-well Transwell dishes (Sigma) at 2 × 105 cells per
well in MTEC/plus. Upon visually reaching confluence
(usually day 9 post-plating), the media was changed
to MTEC/basic plus retinoic acid to enhance differ-
entiation at an air–liquid interface (ALI) [20]. Cells
were harvested at indicated time points and subjected to
immunostaining and immunoblotting. BrdU was added
3 h before cell fixation (ZYMED 00–0103: in vivo
100 µl concentrated reagent per 10 g body weight,
intraperitoneal, 2 h pre-sacrifice; in vitro exp 1 : 100).
In some experiments, cells were incubated overnight
with MTEC/basic medium with no growth factors.
Subcutaneous tumour model
Eight-week-old male, NOD/SCID IL2 Rγ knockout
mice were used for tumourigenesis experiments. All
mouse studies were performed in accordance with
British Home Office procedural and ethical guide-
lines. Animals were housed in pathogen-free conditions
with filtered air, and autoclaved food and water were
available ad libitum . H357 empty vector and LRIG1
transduced cells were injected in a suspension of two
million cells in a total of 200 µl, subcutaneously in the
right flank with a 29 G needle. Tumours were mea-
sured every 2–5 days with callipers, and the volume
was calculated as (4/3)πr3, where r is the estimated
radius [21].
Immunoblotting and immunoprecipitation
Cells were scraped from in vitro cultures into RIPA
buffer supplemented by complete protease inhibitors
(Roche, West Sussex, UK) and phosSTOP phos-
phatase inhibitor (PhosphoSafe Extraction Reagent
Novagen). Equal amounts of protein were loaded and
immunoblotted using the antibodies indicated. Lysates
for immunoprecipitation were prepared by scraping
cells into NP40 buffer [20 mM Tris–HCl (pH 8),
137 mM NaCl, 10% glycerol, 1% Nonidet P-40 (NP-
40), 2 mM EDTA, supplemented by complete pro-
tease inhibitor] at 4◦C on an agitator for 30 min. For
immunoblotting and immunoprecipitation, we used the
following antibodies: phospho-EGFR1 (rabbit; Invitro-
gen), EGFR (rabbit 1005; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), phospho-ERK1/2 (rabbit; Cell
Signaling, Beverley, MA, USA), ERK2 (goat; Santa
Cruz Biotechnology), flag1 (mouse; Sigma), CDH1
(mouse; Watt, CRUK, UK), phospho-Akt (mouse; Cell
Signaling), and β-actin (mouse; Sigma).
In situ hybridization assay
In situ probes were generated from LRIG1 cDNA as
described previously [9]. Hybridization with a β-actin
antisense probe served as a positive control and was
performed as described previously [22].
RNA isolation and quantitative real-time PCR
RNA was extracted from cultured or freshly iso-
lated MTECs and human A549, H357 and BEAS-2b
cells using a commercially available SV RNA isola-
tion kit (Promega, Madison, WI, USA). Carcinoma
in situ (CIS) lesions and a normal area of epithe-
lium biopsied at the same bronchoscopy were laser
microdissected from formalin-fixed, paraffin-embedded
(FFPE) tissues from ten patients. Briefly, multiple
sections of each sample were cut, with the first
and last in a series stained with H&E for inspec-
tion by two lung pathologists. After confirming the
diagnosis and dewax/staining the samples using the
Arcturus Paradise PLUS Reagent System (Applied
Biosystems, Foster City, CA, USA), we laser cap-
ture microdissected the samples using the Zeiss Palm
Microbeam system (Carl Zeiss, Cambridge, UK and
Quanta Biosciences, Leicestershire, UK). RNA was
extracted from both microdissected CIS and normal
lung epithelium FFPE tissues using the RNeasy FFPE
kit (Qiagen, Valencia, CA, USA). RNA concentra-
tion was measured using the Qubit 2.0 Fluorometer
(Invitrogen, Carlsbad, CA, USA). RNA integrity was
analysed using the Agilent 2100 Bioanalyzer (Agi-
lent, Santa Clara, CA, USA). Reverse transcription
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(RT) was performed with qScriptTM cDNA Super-
Mix (Quanta Biosciences) according to the manu-
facturer’s protocol. Real-time quantitative RT-PCR
analysis was executed on an Eppendorf real-time PCR
machine, using TaqMan gene expression assay probes
(Applied Biosystems) for LRIG1 (Hs01006148_m1)
and EGFR (Hs01076073_m1) and TaqMan endoge-
nous control probes (Applied Biosystems) for 18s
rRNA (Hs03928990_g1), β2-M (Hs00187842_m1),
and HPRT (Hs01003267_m1). As the size of most
RNA fragments from typical FFPE samples is around
100 nucleotides, all the TaqMan gene expression assay
and endogenous probes were chosen to produce ampli-
cons as short as possible (lower than 73 nt). Expression
of the LRIG1 and EGFR mRNA was quantified using
the threshold cycle (Ct) method and normalized to the
amount of 18S rRNA, HPRT, and β2-M. The mean of
several Cts of the housekeeping genes had to be lower
than 30, otherwise the sample was treated as unsuitable
for qRT-PCR. Each sample was tested in triplicate and
a sample without template was included in each run as
a negative control.
Loss of heterozygosity (LOH) analysis
AffymetrixSNP 6.0 data were provided by the Well-
come Trust Sanger Institute Cancer Genome Project.
The PICNIC algorithm uses a hidden Markov model
approach to estimate allele-specific integer copy num-
bers [23]. We defined all genomic regions with no
copy of at least one LRIG1 allele as LRIG1 LOH.
Genomic regions showing zero copies of the minor
allele and two or more copies of the major allele
were defined as copy neutral LOH. The percent-
age of cell lines showing no LOH, copy neutral
LOH, and hemizygous deletions was counted for (i)
all lung cancer cell lines and (ii) all squamous cell
lines. The data were obtained from the Wellcome
Trust Sanger Institute Cancer Genome Project website,
http://www.sanger.ac.uk/genetics/CGP.
DNA was extracted from ten microdissected CIS
and ten matched normal lung epithelium FFPE tissues
using the Arcturus PicoPure DNA Extraction
Kit (ABI). LOH was analysed by PCR amplification
using one informative LRIG1 microsatellite marker
(66457092–66457543). The fluorescent-labelled
primer sequences for the microsatellite marker were
(6FAM)-5′-TCTTTAAGAAGACTCCCTGTTTGTT-
3′ and 5′-GCCCCCTGCTGTCAAACT-3′. PCR
reactions were run on an ABI 373 DNA sequencer,
with real-time fluorescence detection of PCR
products. An internal size standard was used in
each lane to give accurate base-pair determina-
tions. Data were inspected using the Peak Scanner
software (ABI).
Allele ratios were determined by measuring the
fluorescence intensity (peak height) of the smaller
(base-pair) allele 1 relative to the FU intensity of the
larger allele 2 (A/B). LOH was determined by assessing
the ratio of peak heights in CIS tissue samples relative
to the ratio in the corresponding normal samples; a
two-fold or greater change in the allelic ratio was
considered evidence of LOH.
Results
Lrig1 loss causes hyperproliferation of the murine
upper airways with increased EGFR phosphorylation
Using immunofluorescence and in situ hybridization,
we showed that normal murine airways express LRIG1
throughout the trachea and first few bronchial divi-
sions (Figures 1a and 1b, day 0/undamaged, and Sup-
plementary Figure 2). LRIG1 is expressed ubiqui-
tously in the airways during steady-state homeostasis
with co-immunofluorescence staining seen with keratin
14-positive cells (basal), Clara-cell secretory protein-
positive cells (Clara cells), and acetylated tubulin-
positive cells (ciliated) (data not shown).
As EGFR signalling is known to be important dur-
ing tissue repair, we first analysed whether Lrig1
expression changes upon airway epithelial damage
after oropharyngeal instillation of the detergent poli-
docanol. By indirect immunofluorescence and in situ
hybridization, we observed a transient reduction in
LRIG1 expression 48 h post-injury (Figures 1a and 1b
and Supplementary Figure 2). This coincided with the
onset of the proliferative phase of the injury response
(Supplementary Figure 3).
In order to determine whether Lrig1 is required
for airway homeostasis, we analysed tissue from the
Lrig1 knockout mouse model [9]. Loss of LRIG1
was confirmed by immunofluorescence (Supplemen-
tary Figure 4a) and caused a significant increase
in epithelial thickness and the number of cells
per 200 µm of basement membrane in the trachea
and first two bronchial generations compared with
littermate controls (mean ± SEM; 24.9 ± 1.2 mm
versus 19.1 ± 1.7 mm; unpaired t-test p = 0.03;
and 118.3 ± 8.9 versus 81.3 ± 3.0; unpaired t-test
p = 0.001, Figures 1c–1f). Ki67 staining of the
trachea and bronchi demonstrated that the increased
thickness is associated with increased proliferation
in the Lrig1−/− airway epithelium (8.6% ± 1.1% of
Lrig1−/− versus 2.4% ± 0.3% of control cells express
Ki67; Mann–Whitney; p = 0.03; Figure 1g). In spite
of the significant changes to the epithelium, the propor-
tion of basal, Clara, and ciliated cells was maintained
upon loss of LRIG1 (Supplementary Figures 4b–4d).
We conclude that LRIG1 controls proliferation within
the upper airways without affecting lineage-specific
differentiation.
In the epidermis, LRIG1 regulates EGFR signalling
[8]. Immunofluorescence staining for activated EGFR
showed increased pEGFR levels in Lrig1 KO mice
during steady-state homeostasis (Figures 1h, day 0,
and 1i). Following injury by polidocanol, the lev-
els of pEGFR increased in control animals in line
with cellular proliferation (Supplementary Figure 3)
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Figure 2. Lrig1−/− (KO) tracheal epithelial cells show continued proliferation at cell confluence in air–liquid interface culture. (a) Diagram
of ALI culture and experimental time points. (b) Immunostaining of BrdU in MTEC culture pre-confluence and corresponding quantification
(KO versus control, 55.9%± 9.5% versus 62.0%± 11.8%, p> 0.05, n= 4). (c) Immunostaining of BrdU in MTEC cultures at day 14 (5
days after cell confluence) showed increased BrdU immunostaining in Lrig1−/− MTECs compared with controls (9.7%± 3.4% versus
0.5%± 0.1%, p= 0.03, n= 4). (d) Co-staining of keratin 14 (K14, green) with BrdU (red) and (e) acetylated tubulin (ACT, red), showing
no difference between KO and control MTEC differentiation at ALI culture day 14 (control cells K14-positive 47.0%± 11.4% versus KO
cells 54.2%± 9.2%, p> 0.05; control cells ACT-positive 17.0%± 2.6% versus KO cells 16.1%± 2.5%, p> 0.05). (f) Immunoblots showing
increased ERK1/2 phosphorylation of KO MTECs compared with controls. Cells were growth factor-starved for 14 h and then stimulated or
not for 30 min with 20 ng/ml EGF. All statistical values, mean± SEM; Mann–Whitney U-test.
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Figure 3. LRIG1 transduction induces density-dependent growth inhibition in human cancer cells and inhibits tumourigenesis. (a) qPCR of
endogenous LRIG1 and EGFR transcripts shows loss of LRIG1 in cancer cells (A549 and H357) compared with control human airway cells
(BEAS-2B). (b, c) Immunostaining of flag in empty vector (EV) and LRIG1flag transduced cells, (b) A549s and (c) H357 cells, with LRIG1
qPCR and immunoblotting for flag confirming expression. (d, e) A549 and (f, g) H357 immunostaining of BrdU in EV and LRIG1 transduced
cells at pre- and post-confluence, with the corresponding histogram of BrdU-positive cells (A549, *p= 0.03). (h–j) LRIG1 transduction
inhibits tumourigenicity in an immunocompromised mouse model. Nine of ten mice grew tumours in the H357-EV cell group, as opposed
to only one of 11 in the LRIG1 transduced group. Original magnification: (b, c)×40; (d–g)×10.
and the difference between Lrig1 KO and control
animals disappeared (Figures 1h, day 2, and 1j). In
control animals, the levels of EGFR activation sub-
sequently returned to normal by day 7, but remained
elevated in the Lrig1−/− mice (Figures 1h, day 7,
and 1k). This is associated with increased prolifer-
ation at day 7 in Lrig1−/− mice compared with lit-
termate controls (32.7% ± 5.1% versus 21.1% ± 4.1%,
Mann–Whitney p = 0.03) (Figure 1l). The dynamic
expression pattern of LRIG1 during injury suggests
that it controls either airway cell differentiation or pro-
liferation. As Lrig1−/− mice display normal epithelial
differentiation (Figure 1), this indicates that LRIG1
controls proliferation.
Lrig1 depletion leads to a failure of
density-dependent growth inhibition in murine
tracheal epithelial cells and human cancer cell lines
To further examine the hyperproliferative phenotype
of the Lrig1−/− mouse airways, we used murine tra-
cheal epithelial cell (MTEC) air–liquid interface (ALI)
cultures [24]. In ALI cultures, the initial prolifera-
tive phase of the culture was carried out submerged
in media until day 9, followed by a differentiation
phase of confluent cells at an ALI (Figure 2a). Pro-
liferation in sub-confluent MTEC cultures was exam-
ined at day 7 in submerged cultures or after mov-
ing to ALI at day 14 by incubating with BrdU 3 h
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Figure 4. LRIG1 reduces EGFR signalling after co-localizing at adherens junctions with EGFR and E-cadherin. (a) Immunoblots of A549-EV
and A549-LRIG1 cells with the indicated antibodies showing LRIG1 reduction in EGFR/ERK phosphorylation. (b) qPCR of E-cadherin (CHD1)
in A549-EV and A549-LRIG1. (c) Immunoblot of A549-EV and A549-LRIG1 cells for E-cadherin. (d) Confocal image of E-cadherin and EGFR
co-localization with immunostaining. (e) EGFR and LRIG1 co-localization; (f) this association was blocked with the addition of EDTA for 2
h to cultures to disrupt the adherens junction. (g) EGFR and (h) E-cadherin immunoprecipitation experiments of cell lysates from A549-EV
and A549-LRIG1 cells show that LRIG1, EGFR, and E-cadherin form a ternary complex at cell confluence (subsequent immunoblots with
the indicated antibodies).
before harvest. Day 7 pre-confluent cultures showed
equivalent cellular proliferation in Lrig1−/− and con-
trol MTECs (Figure 2b). In contrast, proliferation of
Lrig1−/− MTECs post-confluence (day 14) was sig-
nificantly increased compared with littermate controls
(Figure 2c). Cell fate decisions of confluent ALI
Lrig1−/− cultures were again normal, with equivalent
levels of K14 and acetylated tubulin-expressing cells
(Figures 2d and 2e). Protein analysis from Lrig1−/− and
control MTEC cultures demonstrated increased activa-
tion of the EGFR pathway under conditions with and
without the EGF ligand (Figure 2f). Thus, LRIG1 regu-
lates proliferation and EGFR responsiveness in MTEC
cultures.
The loss of contact inhibition in the Lrig1−/− air-
way epithelial cells suggests that LRIG1 may be
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a tumour suppressor in lung cancer cells. Human
lung A549 (adenocarcinoma) and H357 (squamous)
cancer cell lines show little or no expression of
LRIG1 compared with normal human bronchial epithe-
lial cells (BEAS-2B), while having high expres-
sion of EGFR (Figure 3a). These cell lines were
transduced with a retrovirus expression vector encod-
ing a flag-tagged LRIG1 construct or empty vec-
tor control (transduction confirmed by immunoflu-
orescence, immunoblotting, and qPCR, Figures 3b
and 3c) and effects on proliferation were examined
pre- and post-confluence. At pre-confluence, over-
expression of LRIG1 did not affect proliferation
(A549: 78.2% ± 3.8% versus 74.9% ± 4.4%, p > 0.05;
H357: 58.0% ± 6.6% versus 56.1% ± 3.9%, p > 0.05)
(Figures 3d and 3f). However, upon confluence, expres-
sion of exogenous Lrig1 caused a significant reduc-
tion in proliferation (A549s: 13.3% ± 0.7% versus
6.1% ± 1.7%, p = 0.03; H357: 56.3% ± 7.7% versus
40.1% ± 6.9%, p = 0.03) (Figures 3e and 3g). Hence,
the re-expression of LRIG1 is sufficient to restore
cell–cell contact inhibition. Moreover, this is specific
to cancerous cells lines, as normal bronchial epithelial
cells (BEAS-2B cells) that express endogenous LRIG1
show no change in cell proliferation upon expression
of exogenous LRIG1 (Supplementary Figure 5).
To examine LRIG1 effects on tumourigenicity, we
retrovirally transduced the LRIG1-negative human
squamous carcinoma cell line H357 with LRIG1 or
empty vector control and cells were injected subcuta-
neously into immunocompromised mice. In the empty
vector group, nine of ten tumours grew over 7 weeks,
while only one of 11 grew in the LRIG1 transduced
cells (Figures 3h–3j).
LRIG1 complexes with E-cadherin and EGFR at the
adherens junction
In order to understand how LRIG1 affects prolifer-
ation upon cell–cell contact, we first examined the
activation of the EGFR signalling pathways in LRIG1-
null cells compared with LRIG1 transduced cells. We
found that introduction of LRIG1 to human cancer cells
reduced phospho-EGFR levels and the downstream
effecter phospho-ERK1/2, while having no effect on
the activation of Akt (Figure 4a). Homophilic E-
cadherin interactions are known to affect EGFR sig-
nalling in a similar manner [25], and we hypothe-
sized that LRIG1 controls EGFR activity via func-
tional adherens junctions. While LRIG1 transduc-
tion did not alter E-cadherin levels (Figures 4b and
4c), we did, however, observe that EGFR and E-
cadherin, as well as EGFR and LRIG1, co-localized
at cell–cell contacts in a calcium-dependent manner
(Figures 4d–4f). Co-immunoprecipitation experiments
showed a modest interaction between E-cadherin and
EGFR in the absence of LRIG1. This interaction was
greatly enhanced upon LRIG1 transduction, showing
that the three molecules form a ternary complex upon
confluence (Figures 4g and 4h). We conclude that in
both murine tracheal epithelial cells and human lung
cancer cells, LRIG1 is required for effective density-
dependent growth inhibition through inhibition of the
EGFR–ERK1/2 pathway and that it forms a ternary
complex at the cell membrane with E-cadherin and
EGFR upon cell–cell contact.
LRIG1 gene expression is reduced in human
pre-invasive lung cancer samples compared with
patient matched controls and is associated with
LOH in both pre-invasive samples and squamous
cell cancer cell lines
As loss of LRIG1 causes hyperproliferation
in vivo and failure of contact inhibition in vitro,
we hypothesized that LRIG1 loss is an early initiation
step for the development of cancers in the airways.
This will lead to the formation of hyperplastic
lesions and an environment prone to accumulation of
additional genetic abnormalities [26].
mRNA and protein analysis of ten matched samples,
comparing a pre-invasive carcinoma in situ (CIS)
lesion with a normal airway biopsy taken from the
same individual at the same time, showed reduced
gene expression and immunoreactivity for LRIG1 in
pre-invasive tissue compared with normal epithelium
in all ten patients (Figures 5a and 5b). The reduction
in LRIG1 expression was functionally mirrored by
increased EGFR signalling (Figures 5c and 5d). This
strongly identifies loss of LRIG1 as an early event in
the pathogenesis of squamous cell lung cancer.
Several studies have shown that loss of LRIG1
occurs in cancer and is associated with a poor prognosis
[10,11,27–29]. We performed loss of heterozygosity
(LOH) analysis at the LRIG1 locus in 138 lung cancer
and 37 squamous cell carcinoma cell lines as part of
the Sanger Cancer Genome Project, which was carried
out using the Affymetrix SNP6.0 array in conjunction
with a bespoke algorithm (PICNIC: Predicting Integral
Copy Numbers In Cancer) [23]. This analysis showed
that LOH at the LRIG1 locus had occurred in 75% of
the lung cancer cell lines. Fifty-seven per cent of the
cell lines showed copy neutral LOH and 18% showed
hemizygous deletion (Figure 5e). Furthermore, 76% of
the squamous cell carcinoma cell lines including those
from the cervix, lung, head and neck, oesophagus, skin,
tongue, upper aerodigestive tract, upper respiratory
tract, and vulva had LOH of LRIG1 (Figure 5f). In
all but one case, LOH was due to whole-arm loss or
large chromosomal alteration on the 3p region, and so
was not specifically targeted to the LRIG1 locus, but
all do overlap with the LRIG1 locus (Supplementary
Figures 6a and 6b).
Intriguingly, LOH also occurred in pre-invasive
lung cancer lesions. Microsatellite LOH analysis was
performed on the same ten pre-invasive lung cancer
lesions and their patient matched controls using a
heterozygous microsatellite marker within the LRIG1
gene, and revealed LRIG1 LOH in four pre-invasive
lung cancer samples (Figures 5g and 5h). The lack of
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Figure 5. Early loss of LRIG1 in pre-invasive lung cancer lesions. (a) qPCR analysis of relative mRNA expression of LRIG1 in CIS and normal
lung epithelium samples. There was a two-fold change of the LRIG1 mRNA level between CIS (n= 9) and patient matched normal (n= 10)
samples (*p = 0.048). (b) Representative LRIG1 immunostained section of normal human lung epithelium and CIS lesions showing the loss
of LRIG1 in CIS samples compared with patient matched controls. (c) qPCR analysis of relative mRNA expression for EGFR in CIS and normal
lung epithelium samples showing a 2.4-fold change between CIS (n= 9) and normal (n= 10) samples (*p = 0.049). (d) Representative EGFR
immunostaining of human lung CIS and normal epithelial sample showing EGFR up-regulation in CIS samples. (e, f) Frequency of LOH at
the LRIG1 locus in lung and squamous cancer cell lines, respectively, as revealed by analysis of the Sanger Institute SNP-CGH. (g, h) LOH
analysis with microsatellite marker in a matched patient–normal sample showing LOH of the LRIG1 locus.
frozen tissue from these samples meant that we were
unable to examine promoter methylation or seek a gene
mutation in the remaining allele.
Discussion
Our data identify LRIG1 as an important regulator
of tissue homeostasis in the major airways. We have
demonstrated that LRIG1 acts as a tumour suppressor
and forms a ternary complex at adherens junctions with
E-cadherin and EGFR. LRIG1 controls EGFR/ERK1/2
activation upon cell–cell contact. Pre-invasive lung
cancer lesions are characterized by loss of contact
inhibition, increased epithelial proliferation, and ele-
vated EGFR activation [6]. Our findings therefore iden-
tify loss of LRIG1 as an early event in the pathogenesis
of squamous cell lung carcinomas and provide insight
into elevated EGFR activation in pre-invasive lesions.
Copyright  2012 Pathological Society of Great Britain and Ireland. J Pathol 2013; 229: 608–620
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
618 L Lu et al
As loss of LRIG1 has been identified as one of four
key events that predict patient outcome across five
tumour types including 129 lung squamous cell car-
cinoma patients [11], we propose that this may be a
general mechanism for controlling homeostasis in other
epithelial tissues such as the epidermis [7]. This has
widespread implications for the role of cell–cell con-
tact inhibition and regulation of EGFR signalling in
development, tissue homeostasis, and disease.
EGFR and E-cadherin are known to co-localize on
cell–cell contact, as we too have demonstrated. While
E-cadherin protein levels increase five times at cell
confluence, EGFR mRNA and protein levels remain
constant but tyrosine kinase activity is reduced [30].
The mechanism by which EGFR activation is reduced
at cell confluence was not previously understood. A
postulated way of producing this fall in EGFR phos-
phorylation is a direct inhibitory interaction between
E-cadherin and EGFR but to our knowledge there are
no data to support this. Our data show, however, that
the endogenous EGFR inhibitory molecule LRIG1 is
also recruited to the complex at cell confluency and is
required for density-dependent growth inhibition.
LRIG1 is expressed in all tissues [31], and endoge-
nous and synthetic LRIG1 has been confirmed to
be plasma membrane-bound by cell surface biotiny-
lation/precipitation and confocal immunofluorescence
and laser microscopy [19]. Previous data suggest that
LRIG1 blocks EGFR activation through two possi-
ble mechanisms. First, LRIG1 transcript and protein
are known to be up-regulated after EGF stimulation,
which is thought to be a negative feedback mechanism,
whereby it associates with all four EGFR analogues
and both proteins are subsequently ubiquitinated by
ubiquitin ligases [32]. Alternatively, LRIG1 has been
postulated to bind EGFR in a monomeric ‘attenuated’
state. This is because LRIG1 with the intracellular
domain, including c-Cbl E3 ubiquitin ligase binding
domain deleted, still attenuates EGFR activity without
physical down-regulation of the protein and without
competing for EGF binding [33]. Our data suggest that
the latter may be the case in density-dependent growth
inhibition as we see no down-regulation of the EGFR
protein itself but a dramatic fall in EGFR activity at
cell–cell contact with LRIG1 expression.
In our extremely rare human samples of pre-invasive
cancer lesions that have a matched local biopsy of
normal airways, we have demonstrated loss of LRIG1
expression and LOH in four of ten lesions, but none
in normal biopsies. It is tempting to hypothesize that
this goes some way to understanding the mechanism of
LRIG1 loss in the airways of smokers but our samples
had DNA that was too degraded to examine for methy-
lation or mutation abnormalities in the remaining allele.
Our murine data demonstrating a clear phenotypic dif-
ference between Lrig1 -null mice and heterozygotes
mean that the LOH that we see in humans is unlikely
to result in haploinsufficiency as a cause for the human
pre-invasive lesions.
In addition to being unable to definitively define
the genetic cause for loss of LRIG1 expression in
the human pre-invasive lung cancer lesions, a further
weakness in our study is the lack of definitive proof
that the ternary complex formation leads to cell–cell
contact inhibition. We have shown that LRIG1 is
required and that LRIG1 forms a ternary complex
with EGFR and E-cadherin but have not definitively
demonstrated that the complex is necessary. To study
this further, it would be interesting to make a series of
E-cadherin mutants to try to inhibit LRIG1 binding in a
bid to block cell–cell contact inhibition in the presence
of LRIG1.
In summary, we have established LRIG1 as an
important tumour suppressor gene in lung cancer
in vitro and in vivo, with its loss occurring in the
pre-invasive stages of human squamous carcinoma
development. LRIG1 loss appears to be among the
earliest abnormalities occurring in pre-cancerous air-
way epithelium, possibly leading to abnormal areas of
proliferative epithelium that attract subsequent genetic
mutations. Examination of data from expression
profiling of CIS lesions confirms LRIG1 loss in CIS
with a six-fold fall compared with normal epithelium
[34]. Whether this phenotype can be reversed may
have an important impact on future chemopreventative
strategies.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article.
Figure S1. No significant difference in airway epithelial morphology, cellularity or proliferation was found between LRIG1 WT and HET mice.
Figure S2. Deletion of Lrig1 causes hyperproliferation of the upper airways.
Figure S3. Demonstration of polidocanol damage to the upper airways.
Figure S4. Lrig1 deletion does not affect cell fate decisions in vivo.
Figure S5. LRIG1 transduction does not affect density-dependent growth inhibition in normal epithelial BEAS-2B cells with endogenous LRIG1
expression.
Figure S6. (a, b) Regions of allelic loss for each cancer cell line that showed LOH of the LRIG1 locus.
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